search
Back to results

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Primary Purpose

Thrombotic Thrombocytopenic Purpura (TTP)

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
BAX930
Standard of care
Sponsored by
Baxalta now part of Shire
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Thrombotic Thrombocytopenic Purpura (TTP)

Eligibility Criteria

0 Years - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participant or legally authorized representative has provided signed informed consent >= 18 years of age and/or assent form (signed by legal representative if participants is <18 years of age).
  • Participant is 0 to 70 years of age, inclusive, at the time of screening. (Participants < 18 years of age will be enrolled only after at least 5 adults (>= 18 years of age) each have at least 10 exposures with BAX 930 and reviewed by the Data Monitoring Committee (DMC). In France, no participants younger than 18 years of age will be enrolled into the study before the first adult participant has been treated with BAX 930 for a minimum of 6 months.
  • Participant has a documented diagnosis of severe hereditary ADAMTS13 deficiency, defined as:

    • Confirmed by molecular genetic testing, documented in participant history or at screening, and
    • ADAMTS13 activity < 10 % as measured by the fluorescent resonance energy transfer- von Willebrand factor73 (FRETS-VWF73) assay, documented in participant history or at screening (participants currently receiving standard of care (SoC) prophylactic therapy may exceed 10% ADAMTS13 activity at screening).

Note: Participants currently receiving prophylactic therapy will be screened immediately prior to their usual prophylactic infusion

  • Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs (platelet count < 100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (>2)* ULN) at screening. (Prophylactic cohort only).
  • Participant is currently on a prophylactic dosing regimen or has a documented history of at least 1 TTP event and an ability to tolerate SoC prophylactic dosing (prophylactic cohort only).
  • Participants >= 16 years of age must have a Karnofsky score >= 70% and participants < 16 years of age must have a Lansky score >= 80%.
  • Participant is hepatitis C virus (HCV)-negative as confirmed by antibody or polymerase chain reaction testing OR HCV-positive if their disease is chronic but stable.
  • If female of childbearing potential, participant presents with a negative blood or urine pregnancy test, confirmed no more than 7 days before the first administration, and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
  • Sexually active males must use an accepted and effective method of contraception during the treatment and until a minimum of 16 days after the last dose administered.
  • Participant is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

  • Participant has been diagnosed with any other TTP-like disorder (microangiopathic hemolytic anemia), including acquired TTP.
  • Participant has known hypersensitivity to hamster proteins.
  • Participant has experienced an acute TTP event less than 30 days prior to screening (prophylactic cohort only).
  • Participant has a medical history or presence of a functional ADAMTS13 inhibitor at screening.
  • Participant has a medical history of genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including participants who are human immunodeficiency virus (HIV)-positive with an absolute cluster of differentiation 4 (CD4) count < 200/ cubic millimeter (mm^3) or who are receiving chronic immunosuppressive drugs.
  • Participant has been diagnosed with severe cardiovascular disease (New York Heart Association classes 3 to 4).
  • Participant with end stage renal disease requiring chronic dialysis.
  • Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not limited to, any of the following:

    • Serum alanine aminotransferase (ALT) >= 2* ULN.
    • Severe hypoalbuminemia < 24 gram per liter (g/L).
    • Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly, history of esophageal varices).
  • In the opinion of the investigator, the participant has another clinically significant concomitant disease that may pose additional risks for the participant.
  • Participant has been treated with an immunomodulatory drug, excluding topical treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of corticosteroids in conjunction with administration of fresh frozen plasma (FFP) to prevent allergic reactions is permitted.
  • Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylaxis cohort only).
  • Participant is receiving or anticipates receiving another investigational drug and/or interventional drug within 30 days before enrollment.
  • Participant has a history of drug and/or alcohol abuse within the last 2 years.
  • Participant has a progressive fatal disease and/or life expectancy of less than 3 months.
  • Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures.
  • Participant suffers from a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude.
  • Participant is a family member or employee of the sponsor or investigator.
  • If female, participant is pregnant or lactating at the time of enrollment.
  • Any contraindication to SoC medicinal product(s) as per local prescribing information.

Sites / Locations

  • Winship Cancer Institute
  • Alliance for Childhood Diseases, Cure 4 the Kids Foundation
  • Duke University Medical CenterRecruiting
  • Cincinnati Children's Hospital Medical Center
  • Ohio State Univ College Of Medicine
  • University of Oklahoma
  • The Methodist Hospital
  • AKH - Medizinische Universität Wien
  • CHU Saint Etienne - Hôpital NordRecruiting
  • Hopital Claude Huriez - CHU Lille
  • Hôpital Saint-Antoine
  • Hôpital Necker - Enfants MaladesRecruiting
  • Hôpital Robert Debré - ParisRecruiting
  • Universitaetsklinikum JenaRecruiting
  • Universitaetsklinikum Hamburg-EppendorfRecruiting
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
  • Azienda Ospedaliera Universitaria "Policlinico - Vittorio Emanuele" (Presidio Ferrarotto Alessi)Recruiting
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  • Dipartimento di Medicina Traslazionale e di Precisione - "Sapienza" Universita di RomaRecruiting
  • Kyushu University Hospital
  • Hyogo College of Medicine Hospital
  • Medical Hospital, Tokyo Medical and Dental University
  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny
  • Instytut Hematologii i Transfuzjologii
  • Complejo Hospitalario Universitario A CoruñaRecruiting
  • Hospital de Cruces
  • Hospital General Universitario de Alicante
  • Hospital Universitario de Salamanca
  • Hospital Universitario Virgen del Rocio
  • Hospital Universitari i Politecnic La FeRecruiting
  • Inselspital - Universitaetsspital Bern
  • University College London Hospitals
  • Royal Manchester Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Prophylaxis Cohort I

Prophylaxis Cohort II

On Demand Cohort I

On Demand Cohort II

Arm Description

Participants randomized to SOC arm in prophylactic treatment cohort will receive a single dose intravenous (IV) infusions of 40 international units per kilogram (IU/kg) BAX-930 ORT product followed by a PK dose of their current SoC at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for 6 months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.

Participants randomized to BAX-930 arm in prophylactic cohort will receive a PK dose of their current SoC product followed by a single dose IV infusions of 40 IU/kg BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT once Q2W for the next six months followed by SOC for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.

Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.

Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg [+/- 4 IU/kg] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg [+/- 2 IU/kg] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg [+/- 1.5 IU/kg] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.

Outcomes

Primary Outcome Measures

Number of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events
Number of acute TTP events among participants receiving either BAX 930 or standard of care (SoC) prophylactically during the corresponding treatment periods will be assessed.

Secondary Outcome Measures

Percentage of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events Responding to BAX 930
Percentage of acute TTP events responding to BAX 930, is defined as not requiring the use of another a human disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13)-containing agent.
Time to Resolution of Acute TTP Events
Time to resolution of acute TTP events following initiation of treatment with BAX 930 or SoC agent will be assessed.
Number of Participants With Thrombocytopenia
Thrombocytopenia is defined as a drop in platelet count greater than or equal to (>=) 25 percent (%) of baseline or a platelet count less than (<) 150,000/mcgL reported by treatment arm for the prophylactic cohort.
Number of Participants With Microangiopathic Hemolytic Anemia
Microangiopathic hemolytic anemia is defined as an elevation of LDH greater than (>) 1.5* of baseline or >1.5* upper limit of normal (ULN) will be reported by treatment arm for the prophylactic cohort.
Number of Participants With Neurological symptoms
Neurological symptoms includes (e.g., confusion, dysphonia, dysarthria, focal or general motor symptoms including seizures will be reported by treatment arm for the prophylactic cohort.
Number of Participants With Renal Dysfunction
Renal dysfunction is defined as an increase in serum creatinine >1.5*baseline. Number of participants with renal dysfunction will be reported by treatment arm for the prophylactic cohort.
Number of Participants With Abdominal Pain
Number of participants with abdominal pain (TTP related) will be reported by treatment arm for the prophylactic cohort.
Number of Participants With Supplemental Doses
Number of participants with supplemental doses prompted by subacute TTP events will be reported by treatment for the prophylactic cohort.
Number of Participants With Dose Modification
Number of participants with dose modification not prompted by an acute TTP event will be reported by treatment for the prophylactic cohort.
Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events on Their Final Dose
Number of participants with acute TTP events on their final dose and dosing regimen for the prophylactic cohort will be reported.
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is defined as any untoward medical occurrence in a participants administered an IP that does not necessarily have a causal relationship with the treatment. A SAE is defined as an untoward medical occurrence that at any dose meets 1 or more of the following criteria: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly, medically important event (may not be immediately lifethreatening or result in death or require hospitalization but may require medical or surgical intervention to prevent 1 of the other outcomes: intensive treatment, confirmed seroconversion for human immunodeficiency viruses (HIV), severe hypersensitivity/allergic reactions, uncomplicated pregnancies etc). Vital signs, clinical chemistry, hematology will be assessed and reported as AE.
Number of Participants With Antibodies to ADAMTS13
Number of participants with binding and inhibitory antibodies to ADAMTS13 will be reported.
Estimated Total Quantity of ADAMTS13 Administered During the Treatment of Acute TTP Events
Estimated total quantity of ADAMTS13 administered during the treatment of acute TTP events will be assessed. Acute TTP events typically require 3-4 days of intensified treatment.
Incremental Recovery (IR) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
ADAMTS13 activity will be measured by the fluorescent resonance energy transfer (FRETS) assay, ADAMTS13 antigen will be measured using a commercial ADAMTS13 enzyme-linked immunosorbent assay (ELISA) employing ADAMTS13 antigen. IR is defined as body weight normalized maximum increase in plasma ADAMTS13 antigen and activity level. IR of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be assessed.
Area Under the Plasma curve [AUC] of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
AUC of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Terminal Half-Life (T1/2) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
T1/2 of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Mean Residence Time (MRT) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
MRT of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Clearance (CL) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
CL of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Volume at Steady State (Vss) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Vss of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Maximum Concentration (Cmax) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Cmax of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Assessment of Von Willebrand Factor: Antigen (VWF:Ag)
VWF:Ag is a measure of total VWF protein and will be assessed using a sandwich ELISA employing polyclonal anti-human-VWF antibodies. Assessments of VWF:Ag at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment will be reported.
Assessment of Von Willebrand Factor: Ristocetin Cofactor Activity (VWF: RCo)
VWF:RCo will provide a measure of the ability of VWF to bind platelet glycoprotein Ib. Stabilized platelets are agglutinated in the presence of VWF and the antibiotic Ristocetin. Assessments of VWF:RCo at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment will be reported.
Assessment of ADAMTS13 Activity (Pre-Infusion ADAMTS13 Levels) and Select VWF Parameters
Assessment of ADAMTS13 activity (pre-infusion ADAMTS13 levels) and select VWF parameters prior to each PK infusion of SoC or BAX 930 will be reported.
Assessment of Total Binding Antibodies to ADAMTS13
Total binding antibodies to ADAMTS13 will be measured by an ELISA-based assay, detecting total immunoglobulins (IgG, IgA, and IgM). Assessment of total antibodies at baseline, start of each treatment periods and at study completion/early termination will be reported.
Assessment of Neutralizing Antibodies to ADAMTS13
Neutralizing antibodies will be measured by a Bethesda method with Nijmegen modification using the ADAMTS13 FRETS-VWF73 activity assay. Assessment of neutralizing antibodies at baseline, start of each treatment periods and at study completion/early termination will be reported.
Assessment of Anti-Chinese Hamster Ovary (Anti-CHO) Protein Antibodies
Total immunoglobulin antibodies (Immunoglobulin G [IgG], A [IgA], and M [IgM]) against CHO protein will be analyzed using ELISA assay. Anti-CHO protein at baseline, start of each treatment periods and at study completion/early termination will be reported.
Time to Onset of Immunogenic Response to ADAMTS13
Immunogenic response will assessed with the presence of total binding antibodies. Absence of total binding antibodies to ADAMTS13 is an indication of the absence of neutralizing (activity inhibition) antibodies to ADAMTS13. Time to onset of immunogenic response will be reported
Health Related Quality of Life (HRQoL): cTTP-Specific Patient reported outcomes (PROs)
The congenital thrombotic thrombocytopenic purpura (cTTP)-specific patient-reported outcomes (PRO) instrument consists of 26 questions designed to assess the patient's experience of fatigue, joint, muscle, abdominal and chest pain in the previous 24 hours, neurologic manifestations, bruising, feelings of depression and mood alterations, and activity limitation in the past 7 days, and patient's attitudes, experienced side effects, work/school absences and travel impact associated with treatment received for TTP during the previous 2 weeks. The cTTP PRO assessment is focused on measuring the symptoms and impacts of the disease. The scores range from 0 to 152. Higher scores indicate a better quality of life.
Health Related Quality of Life (HRQoL): 36-Item Short Form Health Survey (SF-36)
The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQoL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQoL.
Health Related Quality of Life (HRQoL): Abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)
TSQM is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
Health Related Quality of Life (HRQoL): EuroQol 5 Dimensions Questionnaire 3-Level (EQ-5D-3L)
EQ-5D-3L health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
Health Related Quality of Life (HRQoL): EQ-5D-youth (EQ-5D-Y)
EQ-5D-Y health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
Health Related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (Ped QL)
The Peds QL is a generic health related quality of life instrument designed specifically for a pediatric population and captures following domains: physical functioning, emotional functioning, social functioning, school functioning, psychosocial summary, physical health and total score. The Peds-QL total score consist of all 23 items of all domains. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better quality of life.
Resource Utilization: Length of Hospital Stay for Acute TTP Events
Number of days participants stay in hospital for Acute TTP events will be assessed.
Resource Utilization: Resource Utilization During Prophylaxis
Number of participants utilized during prophylaxis will be assessed.
Resource Utilization: Days Missed From School or Work due to TTP-Related Illness
Number of days missed from school or work due to TTP-related illness will be assessed.

Full Information

First Posted
October 5, 2017
Last Updated
February 27, 2023
Sponsor
Baxalta now part of Shire
Collaborators
Takeda Development Center Americas, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03393975
Brief Title
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Official Title
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 13, 2017 (Actual)
Primary Completion Date
November 1, 2023 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baxalta now part of Shire
Collaborators
Takeda Development Center Americas, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can occur. People who have TTP may bleed underneath the skin forming purple bruises or purpura, or from the surface of the skin. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them leading to lower than normal number of red blood cells. A lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in blood clotting, causes TTP. The enzyme breaks up another blood protein called von Willebrand factor that clumps together with platelets to form blood clots. Some people are born with this condition, others get the condition during their life. Many people who born with TTP experience frequent flareups that need to be treated right away. If not treated It can be fatal or cause lasting damage, such as brain damage or a stroke. BAX 930 is a medicine that replaces ADAMTS13 and can prevent or control TTP flareups, called TTP events. The main aim of this study is to compare the number of TTP events in people born with severe TTP when they treated with BAX 930 versus when they are treated with the standard treatment. Treatment will be given in 2 ways: BAX 930 or standard treatment given to prevent TTP events from happening. BAX 930 or standard treatment given to control an acute TTP event when it happens, according to the clinic's standard practice. Both BAX 930 and standard treatment are given slowly through a vein (infusion). At the first visit, the study doctor will check if you can participate in the study. If you are eligible and enter the study, you will follow an assigned schedule and either start with BAX 930 (Period 1) and then switch to standard treatment (Period 2) or start with standard treatment (Period 1) and then switch to BAX 930 (Period 2). Everyone will be treated with BAX 930 again for Period 3. Each Period will last approximately 6 months. If you enter the study to control an acute TTP event, you will follow a schedule receiving either BAX 930 or standard care to treat your acute TTP event. Once the acute TTP event has gotten better, you can decide to continue in the study and be given treatment to prevent TTP events from happening, following the schedule above. Another study's aim is to assess side effects from treatment with BAX 930 and standard treatment. To do that, the study doctor will ask you questions about your health at each study visit. The study doctors will also check how long BAX 930 stays in the blood of the participants, over time. They will do this from blood samples taken after participants receive their specific infusions of BAX 930. This will happen at different times during the study. 1 month after all treatment has been completed, participants will visit the clinic for a final check-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thrombotic Thrombocytopenic Purpura (TTP)

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Model Description
This is a Phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 in the prophylactic and on-demand treatment of participants with severe congenital thrombotic thrombocytopenic purpura (cTTP).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
57 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Prophylaxis Cohort I
Arm Type
Experimental
Arm Description
Participants randomized to SOC arm in prophylactic treatment cohort will receive a single dose intravenous (IV) infusions of 40 international units per kilogram (IU/kg) BAX-930 ORT product followed by a PK dose of their current SoC at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for 6 months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.
Arm Title
Prophylaxis Cohort II
Arm Type
Experimental
Arm Description
Participants randomized to BAX-930 arm in prophylactic cohort will receive a PK dose of their current SoC product followed by a single dose IV infusions of 40 IU/kg BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT once Q2W for the next six months followed by SOC for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
Arm Title
On Demand Cohort I
Arm Type
Experimental
Arm Description
Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
Arm Title
On Demand Cohort II
Arm Type
Experimental
Arm Description
Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg [+/- 4 IU/kg] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg [+/- 2 IU/kg] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg [+/- 1.5 IU/kg] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
Intervention Type
Biological
Intervention Name(s)
BAX930
Other Intervention Name(s)
rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930
Intervention Description
Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
Intervention Type
Biological
Intervention Name(s)
Standard of care
Intervention Description
Participants will receive Investigator-recommended Standard of care (SoC).
Primary Outcome Measure Information:
Title
Number of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events
Description
Number of acute TTP events among participants receiving either BAX 930 or standard of care (SoC) prophylactically during the corresponding treatment periods will be assessed.
Time Frame
Throughout the study period of approximately 70 months
Secondary Outcome Measure Information:
Title
Percentage of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events Responding to BAX 930
Description
Percentage of acute TTP events responding to BAX 930, is defined as not requiring the use of another a human disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13)-containing agent.
Time Frame
Throughout the study period of approximately 70 months
Title
Time to Resolution of Acute TTP Events
Description
Time to resolution of acute TTP events following initiation of treatment with BAX 930 or SoC agent will be assessed.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Thrombocytopenia
Description
Thrombocytopenia is defined as a drop in platelet count greater than or equal to (>=) 25 percent (%) of baseline or a platelet count less than (<) 150,000/mcgL reported by treatment arm for the prophylactic cohort.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Microangiopathic Hemolytic Anemia
Description
Microangiopathic hemolytic anemia is defined as an elevation of LDH greater than (>) 1.5* of baseline or >1.5* upper limit of normal (ULN) will be reported by treatment arm for the prophylactic cohort.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Neurological symptoms
Description
Neurological symptoms includes (e.g., confusion, dysphonia, dysarthria, focal or general motor symptoms including seizures will be reported by treatment arm for the prophylactic cohort.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Renal Dysfunction
Description
Renal dysfunction is defined as an increase in serum creatinine >1.5*baseline. Number of participants with renal dysfunction will be reported by treatment arm for the prophylactic cohort.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Abdominal Pain
Description
Number of participants with abdominal pain (TTP related) will be reported by treatment arm for the prophylactic cohort.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Supplemental Doses
Description
Number of participants with supplemental doses prompted by subacute TTP events will be reported by treatment for the prophylactic cohort.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Dose Modification
Description
Number of participants with dose modification not prompted by an acute TTP event will be reported by treatment for the prophylactic cohort.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events on Their Final Dose
Description
Number of participants with acute TTP events on their final dose and dosing regimen for the prophylactic cohort will be reported.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Description
An AE is defined as any untoward medical occurrence in a participants administered an IP that does not necessarily have a causal relationship with the treatment. A SAE is defined as an untoward medical occurrence that at any dose meets 1 or more of the following criteria: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly, medically important event (may not be immediately lifethreatening or result in death or require hospitalization but may require medical or surgical intervention to prevent 1 of the other outcomes: intensive treatment, confirmed seroconversion for human immunodeficiency viruses (HIV), severe hypersensitivity/allergic reactions, uncomplicated pregnancies etc). Vital signs, clinical chemistry, hematology will be assessed and reported as AE.
Time Frame
Throughout the study period of approximately 70 months
Title
Number of Participants With Antibodies to ADAMTS13
Description
Number of participants with binding and inhibitory antibodies to ADAMTS13 will be reported.
Time Frame
Throughout the study period of approximately 70 months
Title
Estimated Total Quantity of ADAMTS13 Administered During the Treatment of Acute TTP Events
Description
Estimated total quantity of ADAMTS13 administered during the treatment of acute TTP events will be assessed. Acute TTP events typically require 3-4 days of intensified treatment.
Time Frame
Throughout the study period of approximately 70 months
Title
Incremental Recovery (IR) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Description
ADAMTS13 activity will be measured by the fluorescent resonance energy transfer (FRETS) assay, ADAMTS13 antigen will be measured using a commercial ADAMTS13 enzyme-linked immunosorbent assay (ELISA) employing ADAMTS13 antigen. IR is defined as body weight normalized maximum increase in plasma ADAMTS13 antigen and activity level. IR of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be assessed.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Area Under the Plasma curve [AUC] of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Description
AUC of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Terminal Half-Life (T1/2) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Description
T1/2 of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Mean Residence Time (MRT) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Description
MRT of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Clearance (CL) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Description
CL of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Volume at Steady State (Vss) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Description
Vss of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Maximum Concentration (Cmax) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma
Description
Cmax of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Assessment of Von Willebrand Factor: Antigen (VWF:Ag)
Description
VWF:Ag is a measure of total VWF protein and will be assessed using a sandwich ELISA employing polyclonal anti-human-VWF antibodies. Assessments of VWF:Ag at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Assessment of Von Willebrand Factor: Ristocetin Cofactor Activity (VWF: RCo)
Description
VWF:RCo will provide a measure of the ability of VWF to bind platelet glycoprotein Ib. Stabilized platelets are agglutinated in the presence of VWF and the antibiotic Ristocetin. Assessments of VWF:RCo at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Assessment of ADAMTS13 Activity (Pre-Infusion ADAMTS13 Levels) and Select VWF Parameters
Description
Assessment of ADAMTS13 activity (pre-infusion ADAMTS13 levels) and select VWF parameters prior to each PK infusion of SoC or BAX 930 will be reported.
Time Frame
Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Title
Assessment of Total Binding Antibodies to ADAMTS13
Description
Total binding antibodies to ADAMTS13 will be measured by an ELISA-based assay, detecting total immunoglobulins (IgG, IgA, and IgM). Assessment of total antibodies at baseline, start of each treatment periods and at study completion/early termination will be reported.
Time Frame
Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Title
Assessment of Neutralizing Antibodies to ADAMTS13
Description
Neutralizing antibodies will be measured by a Bethesda method with Nijmegen modification using the ADAMTS13 FRETS-VWF73 activity assay. Assessment of neutralizing antibodies at baseline, start of each treatment periods and at study completion/early termination will be reported.
Time Frame
Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Title
Assessment of Anti-Chinese Hamster Ovary (Anti-CHO) Protein Antibodies
Description
Total immunoglobulin antibodies (Immunoglobulin G [IgG], A [IgA], and M [IgM]) against CHO protein will be analyzed using ELISA assay. Anti-CHO protein at baseline, start of each treatment periods and at study completion/early termination will be reported.
Time Frame
Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Title
Time to Onset of Immunogenic Response to ADAMTS13
Description
Immunogenic response will assessed with the presence of total binding antibodies. Absence of total binding antibodies to ADAMTS13 is an indication of the absence of neutralizing (activity inhibition) antibodies to ADAMTS13. Time to onset of immunogenic response will be reported
Time Frame
Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Title
Health Related Quality of Life (HRQoL): cTTP-Specific Patient reported outcomes (PROs)
Description
The congenital thrombotic thrombocytopenic purpura (cTTP)-specific patient-reported outcomes (PRO) instrument consists of 26 questions designed to assess the patient's experience of fatigue, joint, muscle, abdominal and chest pain in the previous 24 hours, neurologic manifestations, bruising, feelings of depression and mood alterations, and activity limitation in the past 7 days, and patient's attitudes, experienced side effects, work/school absences and travel impact associated with treatment received for TTP during the previous 2 weeks. The cTTP PRO assessment is focused on measuring the symptoms and impacts of the disease. The scores range from 0 to 152. Higher scores indicate a better quality of life.
Time Frame
Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Title
Health Related Quality of Life (HRQoL): 36-Item Short Form Health Survey (SF-36)
Description
The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQoL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQoL.
Time Frame
Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Title
Health Related Quality of Life (HRQoL): Abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)
Description
TSQM is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
Time Frame
Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Title
Health Related Quality of Life (HRQoL): EuroQol 5 Dimensions Questionnaire 3-Level (EQ-5D-3L)
Description
EQ-5D-3L health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
Time Frame
Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Title
Health Related Quality of Life (HRQoL): EQ-5D-youth (EQ-5D-Y)
Description
EQ-5D-Y health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
Time Frame
Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Title
Health Related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (Ped QL)
Description
The Peds QL is a generic health related quality of life instrument designed specifically for a pediatric population and captures following domains: physical functioning, emotional functioning, social functioning, school functioning, psychosocial summary, physical health and total score. The Peds-QL total score consist of all 23 items of all domains. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better quality of life.
Time Frame
Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Title
Resource Utilization: Length of Hospital Stay for Acute TTP Events
Description
Number of days participants stay in hospital for Acute TTP events will be assessed.
Time Frame
Throughout the study period of approximately 70 months
Title
Resource Utilization: Resource Utilization During Prophylaxis
Description
Number of participants utilized during prophylaxis will be assessed.
Time Frame
Throughout the study period of approximately 70 months
Title
Resource Utilization: Days Missed From School or Work due to TTP-Related Illness
Description
Number of days missed from school or work due to TTP-related illness will be assessed.
Time Frame
Throughout the study period of approximately 70 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
0 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participant or legally authorized representative has provided signed informed consent >= 18 years of age and/or assent form (signed by legal representative if participants is <18 years of age). Participant is 0 to 70 years of age, inclusive, at the time of screening. (Participants < 18 years of age will be enrolled only after at least 5 adults (>= 18 years of age) each have at least 10 exposures with BAX 930 and reviewed by the Data Monitoring Committee (DMC). In France, no participants younger than 18 years of age will be enrolled into the study before the first adult participant has been treated with BAX 930 for a minimum of 6 months. Participant has a documented diagnosis of severe hereditary ADAMTS13 deficiency, defined as: Confirmed by molecular genetic testing, documented in participant history or at screening, and ADAMTS13 activity < 10 % as measured by the fluorescent resonance energy transfer- von Willebrand factor73 (FRETS-VWF73) assay, documented in participant history or at screening (participants currently receiving standard of care (SoC) prophylactic therapy may exceed 10% ADAMTS13 activity at screening). Note: Participants currently receiving prophylactic therapy will be screened immediately prior to their usual prophylactic infusion Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs (platelet count < 100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (>2)* ULN) at screening. (Prophylactic cohort only). Participant is currently on a prophylactic dosing regimen or has a documented history of at least 1 TTP event and an ability to tolerate SoC prophylactic dosing (prophylactic cohort only). Participants >= 16 years of age must have a Karnofsky score >= 70% and participants < 16 years of age must have a Lansky score >= 80%. Participant is hepatitis C virus (HCV)-negative as confirmed by antibody or polymerase chain reaction testing OR HCV-positive if their disease is chronic but stable. If female of childbearing potential, participant presents with a negative blood or urine pregnancy test, confirmed no more than 7 days before the first administration, and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing. Sexually active males must use an accepted and effective method of contraception during the treatment and until a minimum of 16 days after the last dose administered. Participant is willing and able to comply with the requirements of the protocol. Exclusion Criteria: Participant has been diagnosed with any other TTP-like disorder (microangiopathic hemolytic anemia), including acquired TTP. Participant has known hypersensitivity to hamster proteins. Participant has experienced an acute TTP event less than 30 days prior to screening (prophylactic cohort only). Participant has a medical history or presence of a functional ADAMTS13 inhibitor at screening. Participant has a medical history of genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including participants who are human immunodeficiency virus (HIV)-positive with an absolute cluster of differentiation 4 (CD4) count < 200/ cubic millimeter (mm^3) or who are receiving chronic immunosuppressive drugs. Participant has been diagnosed with severe cardiovascular disease (New York Heart Association classes 3 to 4). Participant with end stage renal disease requiring chronic dialysis. Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not limited to, any of the following: Serum alanine aminotransferase (ALT) >= 2* ULN. Severe hypoalbuminemia < 24 gram per liter (g/L). Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly, history of esophageal varices). In the opinion of the investigator, the participant has another clinically significant concomitant disease that may pose additional risks for the participant. Participant has been treated with an immunomodulatory drug, excluding topical treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of corticosteroids in conjunction with administration of fresh frozen plasma (FFP) to prevent allergic reactions is permitted. Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylaxis cohort only). Participant is receiving or anticipates receiving another investigational drug and/or interventional drug within 30 days before enrollment. Participant has a history of drug and/or alcohol abuse within the last 2 years. Participant has a progressive fatal disease and/or life expectancy of less than 3 months. Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures. Participant suffers from a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude. Participant is a family member or employee of the sponsor or investigator. If female, participant is pregnant or lactating at the time of enrollment. Any contraindication to SoC medicinal product(s) as per local prescribing information.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shire Contact
Phone
+1 866 842 5335
Email
ClinicalTransparency@takeda.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Study Director
Organizational Affiliation
Shire
Official's Role
Study Director
Facility Information:
Facility Name
Winship Cancer Institute
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Completed
Facility Name
Alliance for Childhood Diseases, Cure 4 the Kids Foundation
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89135
Country
United States
Individual Site Status
Completed
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
919-684-5350
Email
thomas.ortel@duke.edu
First Name & Middle Initial & Last Name & Degree
Thomas Ortel
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Individual Site Status
Completed
Facility Name
Ohio State Univ College Of Medicine
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Completed
Facility Name
University of Oklahoma
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Completed
Facility Name
The Methodist Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Completed
Facility Name
AKH - Medizinische Universität Wien
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Completed
Facility Name
CHU Saint Etienne - Hôpital Nord
City
Saint-Priest-en-Jarez cedex
State/Province
Loire
ZIP/Postal Code
42270
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33477828038
Email
claire.berger@chu-st-etienne.fr
First Name & Middle Initial & Last Name & Degree
Claire Berger
Facility Name
Hopital Claude Huriez - CHU Lille
City
Lille
State/Province
Nord
ZIP/Postal Code
59037
Country
France
Individual Site Status
Completed
Facility Name
Hôpital Saint-Antoine
City
Paris cedex 12
State/Province
Paris
ZIP/Postal Code
75571
Country
France
Individual Site Status
Completed
Facility Name
Hôpital Necker - Enfants Malades
City
Paris cedex 15
State/Province
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33144497210
Email
nathalie.biebuyck@aphp.fr
First Name & Middle Initial & Last Name & Degree
Nathalie Biebuyck
Facility Name
Hôpital Robert Debré - Paris
City
Paris
ZIP/Postal Code
75019
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33140032467
Email
claire.dossier@aphp.fr
First Name & Middle Initial & Last Name & Degree
Claire Dossier
Facility Name
Universitaetsklinikum Jena
City
Jena
State/Province
Thueringen
ZIP/Postal Code
07747
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+4936418769
Email
karim.kentouche@med.uni-jena.de
First Name & Middle Initial & Last Name & Degree
Karim Kentouche
Facility Name
Universitaetsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+4940741053796
Email
hassenpflug@uke.de
First Name & Middle Initial & Last Name & Degree
Wolf-Achim Hassenpflug
Facility Name
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
City
Bergamo
ZIP/Postal Code
24127
Country
Italy
Individual Site Status
Completed
Facility Name
Azienda Ospedaliera Universitaria "Policlinico - Vittorio Emanuele" (Presidio Ferrarotto Alessi)
City
Catania
ZIP/Postal Code
90124
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+39953781994
Email
gaegiuffrida@gmail.com
First Name & Middle Initial & Last Name & Degree
Gaetano Giuffrida
Facility Name
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
City
Milano
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
City
Roma
ZIP/Postal Code
168
Country
Italy
Individual Site Status
Completed
Facility Name
Dipartimento di Medicina Traslazionale e di Precisione - "Sapienza" Universita di Roma
City
Rome
ZIP/Postal Code
00161
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Email
chistolini@bce.uniroma1.it
First Name & Middle Initial & Last Name & Degree
Antonio Chistollini
Facility Name
Kyushu University Hospital
City
Fukuoka-shi
State/Province
Fukuoka-Ken
ZIP/Postal Code
812-8582
Country
Japan
Individual Site Status
Completed
Facility Name
Hyogo College of Medicine Hospital
City
Nishinomiya-shi
State/Province
Hyogo-Ken
ZIP/Postal Code
663-8501
Country
Japan
Individual Site Status
Completed
Facility Name
Medical Hospital, Tokyo Medical and Dental University
City
Bunkyo-ku
State/Province
Tokyo-To
ZIP/Postal Code
113-8519
Country
Japan
Individual Site Status
Completed
Facility Name
Samodzielny Publiczny Dzieciecy Szpital Kliniczny
City
Warszawa
ZIP/Postal Code
02-091
Country
Poland
Individual Site Status
Completed
Facility Name
Instytut Hematologii i Transfuzjologii
City
Warszawa
ZIP/Postal Code
02-776
Country
Poland
Individual Site Status
Completed
Facility Name
Complejo Hospitalario Universitario A Coruña
City
A Coruña
State/Province
La Coruña
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
34981176668
Email
Maria.fernada.lopez.fernandez@sergas.es
First Name & Middle Initial & Last Name & Degree
Maria Fernanda Lopez Fernandez
Facility Name
Hospital de Cruces
City
Barakaldo
State/Province
Vizcaya
ZIP/Postal Code
48903
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital General Universitario de Alicante
City
Alicante
ZIP/Postal Code
3010
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital Universitario de Salamanca
City
Salamanca
ZIP/Postal Code
37007
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital Universitario Virgen del Rocio
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital Universitari i Politecnic La Fe
City
València
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+34961244865
Email
sbonanad@gmail.com
First Name & Middle Initial & Last Name & Degree
Santiago Bonanad
Facility Name
Inselspital - Universitaetsspital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Withdrawn
Facility Name
University College London Hospitals
City
London
State/Province
Greater London
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Individual Site Status
Completed
Facility Name
Royal Manchester Children's Hospital
City
Manchester
ZIP/Postal Code
M139WL
Country
United Kingdom
Individual Site Status
Completed

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD Sharing Access Criteria
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD Sharing URL
https://vivli.org/ourmember/takeda/
Links:
URL
https://clinicaltrials.takeda.com/study-detail/5f6b5fc84db2bf003ab4602d
Description
To obtain more information on the study, click here/on this link

Learn more about this trial

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

We'll reach out to this number within 24 hrs